Editorial

HIV Treat Bull - 2009 May-Jun;10(5/6): 01

Welcome to the May/June 2009 issue of HTB which contains a wealth of conference reports including the recent BHIVA meeting in Liverpool, the PK workshop in Amsterdam and additional report from Retrovirus/CROI earlier in the year.

Several issues recur and remaining unresolved. They are likely to be informed by additional research throughout the year.

Cardiovascular disease in the aging HIV population which has higher levels of risk factors than the general population (smoking, lipids, recreational drug use etc) is clearly important. Although the SMART study showed that suppressed viral load from ARV treatment is a protective factor, individual drugs evidently have different CVD profiles, notably abacavir and now lopinavir/r (Kaletra). We include CROI reports, a disturbing case study presented at GSKs satelitte meeting at the BHIVA conference, and the EMEA statement on this complex area.

The recommendations for when to start treatment will also continue to be informed by data likely to show a protective impact at higher CD4 counts. As the investigators from the START trial (which has now enrolled the first patients in the US) point out in their response to published results from a US cohort dataset, the risks as well as benefits will only become clear in a randomised clinical trial and it needs to be large enough to be powered to address risk of low incidence events.

Other reports from CROI focus on women’s health and paediatric care, especially the difficulties of dosing, formulations and drug interactions.

Drug interactions are again highlighted in reports from the PK Workshop and from the Liverpool drug interaction site including a potential interaction between raltegravir and etravirine, and new interaction charts on ARVs and drugs to treat flu and swine flu.

Finally, we include two reviews by Richard Jefferys on studies looking at the role of the gut and microbial translocation.

Happy reading...

Supplements with this issue

We include two supplements with this issue.

The first is the 2009 update to Introduction to Combination Therapy. This is probably the most widely used resource for newly diagnosed patients in the UK and by patients prior to starting treatment.

The second is a reprint of the ‘treatment passport’ that, despite its unassuming cover, is a resource developed with the HIV pharmacists group and the Royal Free to help people track their treatment history.

As with all publications, additional copies of both booklets are available free, including in bulk for use in UK clinics – please order in the usual way.

2009-05-10
IB2009-05-01

©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.